Asia Pacific Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User

The Asia Pacific deep brain simulation market is expected to grow from US$ 98.35 million in 2022 to US$ 188.04 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.

Technological Advancements and Approvals in Deep Brain Stimulation Drive Asia Pacific Deep Brain Simulation Market

Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects. According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the Asia Pacific deep brain stimulation market during the forecast period.

Asia Pacific Deep Brain Simulation Market Overview

China is home to the world's largest population of older adults. According to a study published in The Lancet titled “China's Aging Population: Crisis or Opportunity?” in 2019, people in China aged 60 or older were ~254 million. By 2040, that number is expected to rise to 402 million, ~28% of the population. These changes have profound public health implications in the country as the risk and burden of noncommunicable diseases increase along with the demand for health and social care systems. Parkinson's disease (PD) is a common neurodegenerative disease in the country. According to ChinaDaily, there were approximately 4 million Parkinson's patients in China as of February 2023, and ~1.7% of people over 65 years have been diagnosed with the disease. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in the treatment of Parkinson's disease (PD). With advancements in DBS hardware, researchers have developed several novel programming technologies, of which remote programming is widely used in China. Since 2018, we have been performing remote programming for patients suffering from PD using PINS products (PINS Medical, Ltd., Beijing, China). For patients with advanced Parkinson's disease (over a 15-year time horizon), DBS is considered to be a highly effective treatment option. However, DBS remains a significant economic burden on the patient when not reimbursed, unlike in any other developed country. In China, the surgery cost is mainly covered by the patient's health insurance, but the cost of DBS hardware is only partially covered, which can hamper the growth of the market in the country.

Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Deep Brain Simulation Market Segmentation

The Asia Pacific deep brain simulation market is segmented into product, application, end user, and country.

Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Asia Pacific deep brain simulation market.

Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. In 2022, the Parkinson’s disease segment registered the largest share in the Asia Pacific deep brain simulation market.

Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Asia Pacific deep brain simulation market.

Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. In 2022, China segment registered the largest share in the Asia Pacific deep brain simulation market.

Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd are some of the leading companies operating in the Asia Pacific deep brain simulation market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific deep brain simulation market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific deep brain simulation market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the deep brain simulation market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution